Literature DB >> 11204721

Coordinate expression of matrix-degrading proteinases and their activators and inhibitors in bovine skeletal muscle.

D Balcerzak1, L Querengesser, W T Dixon, V E Baracos.   

Abstract

Matrix metalloproteinases (MMP) responsible for degradation of connective tissue are found in most tissues. The MMP are regulated at the levels of transcription, zymogen activation by plasmin or membrane-type- (MT) MMP, and control of enzyme activity by tissue inhibitors of metalloproteinases (TIMP). Whole bovine skeletal muscle showed multiple MMP activities on gelatin zymography and also expressed mRNA encoding MMP-1, -2, -9, -14, and -16, tissue inhibitors of metalloproteinase (TIMP)-1, -2, and -3 and plasminogen activator and its receptor. Purified intramuscular fibroblasts and myogenic cell culture derived from satellite cells expressed most or all of these elements. Statistical analysis (n = 35) revealed a strong positive correlation among the mRNA levels of several elements of the MMP system, including MMP-2, MMP-14, TIMP-1, -2, and -3 (r = 0.614 to 0.930, P < 0.0001). Our results provide an extensive profile of an extracellular proteolytic cascade involving MMP in skeletal muscle and suggest that 1) the activation cascades of muscle MMP may be initiated by both plasmin and membrane-type MMP; 2) a group of genes involved in the same "arm" of zymogen activation are coexpressed in this tissue; and 3) skeletal muscle cells, in addition to the intramuscular fibroblasts, express an extensive complement of MMP and related proteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11204721     DOI: 10.2527/2001.79194x

Source DB:  PubMed          Journal:  J Anim Sci        ISSN: 0021-8812            Impact factor:   3.159


  8 in total

1.  Muscle CD31(-) CD45(-) side population cells promote muscle regeneration by stimulating proliferation and migration of myoblasts.

Authors:  Norio Motohashi; Akiyoshi Uezumi; Erica Yada; So-ichiro Fukada; Kazuhiro Fukushima; Kazuhiko Imaizumi; Yuko Miyagoe-Suzuki; Shin'ichi Takeda
Journal:  Am J Pathol       Date:  2008-07-31       Impact factor: 4.307

Review 2.  Invited review: mesenchymal progenitor cells in intramuscular connective tissue development.

Authors:  Z G Miao; L P Zhang; X Fu; Q Y Yang; M J Zhu; M V Dodson; M Du
Journal:  Animal       Date:  2015-09-09       Impact factor: 3.240

3.  Distribution and activation of matrix metalloproteinase-2 in skeletal muscle fibers.

Authors:  Xiaoyu Ren; Graham D Lamb; Robyn M Murphy
Journal:  Am J Physiol Cell Physiol       Date:  2019-06-26       Impact factor: 4.249

4.  Inhibition of matrix metalloproteinases suppresses the migration of skeletal muscle cells.

Authors:  Takanori Nishimura; Kazuki Nakamura; Yasuhiro Kishioka; Yuko Kato-Mori; Jun-ichi Wakamatsu; Akihito Hattori
Journal:  J Muscle Res Cell Motil       Date:  2008-06-19       Impact factor: 2.698

5.  Matrix metalloproteinase-2-deficient fibroblasts exhibit an alteration in the fibrotic response to connective tissue growth factor/CCN2 because of an increase in the levels of endogenous fibronectin.

Authors:  Cristian A Droppelmann; Jaime Gutiérrez; Cecilia Vial; Enrique Brandan
Journal:  J Biol Chem       Date:  2009-03-09       Impact factor: 5.157

6.  MMP-14 is necessary but not sufficient for invasion of three-dimensional collagen by human muscle satellite cells.

Authors:  Dane K Lund; Vincent Mouly; D D W Cornelison
Journal:  Am J Physiol Cell Physiol       Date:  2014-06-04       Impact factor: 4.249

7.  Immunological analysis of aerobic bioreactor bovine theileriosis vaccine.

Authors:  Gholamreza Habibi; Kasra Esmaeil-Nia; Hasan Izadi; Orang Ataie Amarloie; Asghar Afshari; Nadia Bordbar
Journal:  Iran J Parasitol       Date:  2014-09       Impact factor: 1.012

8.  Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ).

Authors:  Kazuhiro Fukushima; Akinori Nakamura; Hideho Ueda; Katsutoshi Yuasa; Kunihiro Yoshida; Shin'ichi Takeda; Shu-ichi Ikeda
Journal:  BMC Musculoskelet Disord       Date:  2007-06-28       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.